Stock Screener App

無料 - Play StoreApp Store

インストールインストール

REPL

$19.4910.68%1.88

プレマーケット: 19.62+0.13 +0.67%

Replimune Group Inc (REPL)

Date: O: H: L: C: Vol:

Replimune Group Inc (REPL) 最新ニュース

Replimune Group Stock Price Forecast. Should You Buy REPL? - StockInvest.us

Replimune Group, Inc. (REPL) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Replimune Group (REPL) Launches TUDRIQEV with Early Adoption Ami - GuruFocus

Replimune: 3 Key Takeaways for Long-Term Investors - Yahoo Finance

Replimune: 3 Key Takeaways for Long-Term Investors - The Motley Fool

Replimune Group, Inc. Q2 2027 Earnings Call Summary - Yahoo Finance

Replimune Group, Inc. Stock 12‑Month Price Target Raised to $20.14, Implies 54% Upside - TradingView

Replimune Group stock hits 52-week high at 16.39 USD - Investing.com

Replimune Group, Inc. reports results for the quarter ended September 30 - Earnings Summary - TradingView

Replimune Group Q2 2027 Earnings Call Transcript - Benzinga

Q2 2027 Replimune Group, Inc. Earnings Call Transcript - GuruFocus

Replimune Group 3Q 2026: Revenue $0 Net loss $57.1M, EPS ($0.54) — 10-Q Summary - TradingView

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss - TradingView

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update - Moomoo

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update - Yahoo Finance

Replimune Group (Nasdaq:REPL) - Stock Analysis - Simply Wall St

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 - Yahoo Finance

7R8.DU interactive stock chart | Replimune Group Inc. R stock - Yahoo Finance Australia

Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors - GlobeNewswire Inc.

Replimune Group Inc (7R8.DU) stock price, news, quote and history - Yahoo Finance Australia

Replimune Group Inc (7R8.DU) interactive stock chart - Yahoo Finance Australia

Replimune Group (REPL) Stock Looks Rich After A 141% Run - Yahoo Finance

Replimune Group: A Hold Until TUDRIQEV’s Commercial Potential Becomes Clear (NASDAQ:REPL) - Seeking Alpha

Why Is REPL Stock Soaring 127% After Hours Today? - Stocktwits

Replimune Group, Inc. (REPL) Options Chain - Yahoo! Finance Canada

Replimune Group, Inc. (REPL) Stock Price, News, Quote & History - Yahoo! Finance Canada

Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus - Yahoo Finance

(REPL) Movement as an Input in Quant Signal Sets - Stock Traders Daily

7R8.HM Interactive Stock Chart | Replimune Group Inc. R Stock - Yahoo! Finance Canada

Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire

FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week - Stocktwits

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV

Replimune Group, Inc. (REPL) Options Chain - Yahoo! Finance Canada

Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire

Securities Lawsuit Alert: Replimune Group, Inc. (REPL) - Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire

Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before October 5, 2026 - Contact Levi & Korsinsky - ACCESS Newswire

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & - GlobeNewswire

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & - GlobeNewswire

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th - GlobeNewswire Inc.

Insiders At Replimune Group Sold US$1.6m In Stock, Alluding To Potential Weakness - Moomoo

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm - FinancialContent

Replimune Group, Inc. (7R8.MU) stock price, news, quote and history - Yahoo Finance Australia

Replimune launches melanoma therapy in US market - Investing.com

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - FinancialContent

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - Yahoo Finance

Replimune CEO and CFO sued for allegedly mislea... - Pluang

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL - PR Newswire

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL - TradingView

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky - Morningstar

REPLに類似

PGEN$5.1425.94%

MESO$14.544.09%

TRAX$45.050.07%

BRVE$21.042.19%

ZBIO$27.622.71%